Editorial Comment to Epidemiology of prostate cancer in Asian countries

Sakamoto, Shinichi

doi:10.1111/iju.13707

Cited by 5 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…96 In China, the majority of the patients with PCa have already been diagnosed as progressed to advanced stages, thus losing out on the best operation time. 97,98 Limited and hormone-refractory PCas show a significant upregulation of fascin-1 expression than that in benign prostate tissue. 6,68,69,99 In addition, a follow-up of patients undergoing radical prostatectomy has shown high fascin-1 expression to be related to an increased rate of PSA recurrence.…”

Section: Fascin-1 and Pcamentioning

confidence: 91%

See 1 more Smart Citation

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Zhang,

Bian,

Gao

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Human cancer statistics show that an increased incidence of urologic cancers such as bladder cancer, prostate cancer, and renal cell carcinoma. Due to the lack of early markers and effective therapeutic targets, their prognosis is poor. Fascin-1 is an actin-binding protein, which functions in the formation of cell protrusions by cross-linking with actin filaments. Studies have found that fascin-1 expression is elevated in most human cancers and is related to outcomes such as neoplasm metastasis, reduced survival, and increased aggressiveness. Fascin-1 has been considered as a potential therapeutic target for urologic cancers, but there is no comprehensive review to evaluate these studies. This review aimed to provide an enhanced literature review, outline, and summarize the mechanism of fascin-1 in urologic cancers and discuss the therapeutic potential of fascin-1 and the possibility of its use as a potential marker. We also focused on the correlation between the overexpression of fascin-1 and clinicopathological parameters. Mechanistically, fascin-1 is regulated by several regulators and signaling pathways (such as long noncoding RNA, microRNA, c-Jun N-terminal kinase, and extracellular regulated protein kinases). The overexpression of fascin-1 is related to clinicopathologic parameters such as pathological stage, bone or lymph node metastasis, and reduced disease-free survival. Several fascin-1 inhibitors (G2, NP-G2-044) have been evaluated in vitro and in preclinical models. The study proved the promising potential of fascin-1 as a newly developing biomarker and a potential therapeutic target that needs further investigation. The data also highlight the inadequacy of fascin-1 to serve as a novel biomarker for prostate cancer.

show abstract

Section: Fascin-1 and Pcamentioning

confidence: 91%

“… 96 In China, the majority of the patients with PCa have already been diagnosed as progressed to advanced stages, thus losing out on the best operation time. 97 , 98 …”

Section: Fascin-1 and Pcamentioning

confidence: 99%

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

Zhang,

Bian,

Gao

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PCa) is one of the most prevalent urological cancers in men worldwide [1][2][3]. The incidence of PCa is increased worldwide in recent years [4][5]. In the USA and Europe, PCa accounts for the second most leading cause of cancer-related mortality [6][7].…”

Section: Introductionmentioning

confidence: 99%

BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway

et al. 2021

View full text Add to dashboard Cite

Background Recently, basic leucine zipper and the W2 domain-containing protein 1 (BZW1) is reported to be implicated in tumor progression. However, the role of BZW1 in prostate cancer remains unknown. This study is aimed to investigate the expression of BZW1 and its in uence on cell proliferation in prostate cancer.Methods The expression levels of BZW1 were measured in 136 cases of prostate cancer and matched adjacent non-cancerous prostate tissues by quanti cational real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Then, the effect of BZW1 on cell proliferation was further explored.Results QRT-PCR analysis shown that the mRNA levels of BZW1 in prostate cancer were signi cantly greater compared with those in matched adjacent non-cancerous prostate tissues (P<0.001). IHC results shown the high-expression rate of BZW1 in prostate cancer and matched adjacent non-cancerous prostate tissues were 68.4% and 32.4%, and the difference was statistically signi cant (P<0.001). BZW1 high-expression signi cantly correlated with T stage, lymph node metastasis, prostate speci c antigen (PSA) and Gleason score (P<0.05). Patients with BZW1 high-expression presented unfavorable prognosis compared with those with BZW1 low-expression (P=0.002). In addition, CCK-8 and Colony formation assays revealed that BZW1 over-expression signi cantly promoted cell proliferation in vitro. Tumor xenograft shown BZW1 knockdown signi cantly inhibited tumor growth in vivo. Moreover, BZW1 overexpression activated the TGF-β1/Smad1/Smad3 pathway. Conclusion BZW1 over-expression predicts poorer prognosis and promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway.

show abstract

“…Prostate cancer is the second most frequently diagnosed cancer and the fifth leading cause of cancer death in men all around the world, with approximately 1,600,000 newly diagnosed cases and 366,000 prostate cancer-related deaths each year (1)(2)(3)(4)(5)(6). Metastatic castration-resistant prostate cancer (mCRPC), the advanced stage of prostate cancer, happens in about 10-20% prostate cancer patients within 5 years after initial diagnosis (5,(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Enzalutamide alleviates anxiety and depression as well as improves quality of life compared to bicalutamide in metastatic castration-resistant prostate cancer patients: a cohort study

Guo

2019

Transl. Cancer Res.

View full text Add to dashboard Cite

Background: This study aimed to evaluate the efficacy of enzalutamide compared with bicalutamide on anxiety, depression and quality of life (QoL) in metastatic castration-resistant prostate cancer (mCRPC) patients.Methods: Totally 134 mCRPC patients were consecutively enrolled and baseline data were documented, among whom 53 patients received enzalutamide as Enzalutamide group, while 81 patients received bicalutamide as Bicalutamide group. Anxiety and depression were assessed by Hospital Anxiety and Depression Scale (HADS) as well as Zung Self-Rating Anxiety/Depression Scale (SAS/SDS), and QoL was assessed by Functional Assessment of Cancer Therapy (FACT)-General/Prostate (FACT-G/FACT-P) questionnaires at W0 (baseline), W12, W24, W36, W48 and W60.Results: No difference of HADS-anxiety (HADS-A), SAS, HADS-depression (HADS-D), SDS, FACT-G or FACT-P score at baseline was observed between Enzalutamide group and Bicalutamide group. Both HADS-A score and SAS score were decreased at W48 and W60 in Enzalutamide group compared to Bicalutamide group. HADS-D score was reduced at W60 and SDS score was attenuated at W48 and W60 in Enzalutamide group compared to Bicalutamide group. As to QoL assessments, FACT-G score disclosed no difference at each visit between Enzalutamide group and Bicalutamide group, while FACT-P score was decreased at W60 in Enzalutamide group compared to Bicalutamide group. In addition, the reduction of HADS-A, SAS, HADS-D, SDS, FACT-G and FACT-P scores from W0 to W60 were all higher in in Enzalutamide group compared to Bicalutamide group. Conclusions:In conclusion, enzalutamide presents with better efficacy on alleviating anxiety and depression, as well as improving QoL in mCRPC patients compared to bicalutamide.

show abstract

Editorial Comment to Epidemiology of prostate cancer in Asian countries

Cited by 5 publications

References 3 publications

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?

BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway

Enzalutamide alleviates anxiety and depression as well as improves quality of life compared to bicalutamide in metastatic castration-resistant prostate cancer patients: a cohort study

Contact Info

Product

Resources

About